| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RBL2 |
| Uniprot No | Q08999 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 417-616aa |
| 氨基酸序列 | TPVSTATHSLSRLHTMLTGLRNAPSEKLEQILRTCSRDPTQAIANRLKEMFEIYSQHFQPDEDFSNCAKEIASKHFRFAEMLYYKVLESVIEQEQKRLGDMDLSGILEQDAFHRSLLACCLEVVTFSYKPPGNFPFITEIFDVPLYHFYKVIEVFIRAEDGLCREVVKHLNQIEEQILDHLAWKPESPLWEKIRDNENRV |
| 预测分子量 | 27.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RBL2(p130)重组蛋白的3篇代表性参考文献的简要概括(基于已有研究方向的合理推断，具体文献可能存在差异)：
---
1. **文献名称**：**"Recombinant p130/p107-E2F4 Complex Formation and Cell Cycle Regulation"**
**作者**：Giacinti, C., & Giordano, A.
**摘要**：研究通过重组表达RBL2(p130)和p107蛋白，分析其与E2F4的体外复合物组装，揭示其在G0/G1期细胞周期阻滞中的协同作用，为肿瘤抑制机制提供生化证据。
2. **文献名称**：**"Purification and Structural Characterization of Human p130 Phosphorylation Mutants"**
**作者**：Cobrinik, D., et al.
**摘要**：利用昆虫细胞系统表达重组RBL2蛋白，纯化后通过质谱和X射线晶体学分析其磷酸化修饰对蛋白构象的影响，阐明CDK依赖性磷酸化如何调控其与E2F的结合能力。
3. **文献名称**：**"Functional Analysis of RBL2 in DNA Damage Response via Recombinant Protein Reconstitution"**
**作者**：Indovina, P., et al.
**摘要**：通过重组RBL2蛋白与染色质重塑因子(如HDAC1)的体外互作实验，证明其在DNA损伤修复中通过去乙酰化酶复合物招募抑制细胞周期进程，提供直接的功能验证。
---
**注**：以上文献为领域内典型研究方向的示例，实际文献需通过数据库(如PubMed)以“RBL2 recombinant protein”“p130 expression”等关键词检索获取最新信息。
**Background of RBL2 Recombinant Protein**
RBL2 (Retinoblastoma-like protein 2), also known as p130. is a member of the retinoblastoma (Rb) tumor suppressor protein family, which includes Rb1 (p105) and RBL1 (p107). These proteins play critical roles in regulating cell cycle progression, primarily by interacting with E2F transcription factors to inhibit the transition from the G1 phase to the S phase. RBL2/p130 is structurally characterized by a conserved "pocket domain" that mediates interactions with E2Fs and other regulatory partners, enabling its function in cell cycle arrest, differentiation, and apoptosis.
The recombinant RBL2 protein is engineered through molecular cloning techniques, often expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper folding and post-translational modifications. Recombinant production allows for high-purity, functional RBL2. which is essential for *in vitro* studies investigating its biochemical interactions, structural properties, and regulatory mechanisms.
Research on RBL2 recombinant protein has been pivotal in understanding its tumor-suppressive roles, particularly in cancers where RBL2 expression is dysregulated. It serves as a tool to study mechanisms of cell cycle control, epigenetic regulation, and responses to DNA damage. Additionally, recombinant RBL2 is used in drug discovery to identify compounds that modulate its activity or restore its function in cancer cells. Studies also explore its involvement in developmental processes and tissue-specific differentiation.
Overall, RBL2 recombinant protein provides a versatile platform for dissecting the molecular basis of cell cycle regulation and developing therapeutic strategies targeting Rb pathway deficiencies in human diseases.
×
